{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '2.', 'Any disease-directed radiotherapy (except PCI, palliative radiotherapy to a', 'radiographically documented non-progressing lesion for symptom control, or pre-', 'planned radiotherapy for CNS metastases present prior to start of first-line therapy', 'and non-progressing) after last dose of first-line chemotherapy.', '3.', 'Any significant medical condition including any suggested by screening laboratory', 'findings that in the opinion of the Investigator or Sponsor may place the subject at', 'undue risk from the study.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '(NYHA) Class III - IV heart failure (refer to Appendix F) within 6 months prior to', 'randomization.', '5.', 'Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization', 'or earlier history of recurrent Grade 2 or higher effusions with ongoing requirement', 'for pericardiocentesis or thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or', 'higher (per NCI CTCAE version 4.0)11 viral, bacterial, or fungal infection.', '8.', 'Female subject who is pregnant, breastfeeding or is considering becoming pregnant', 'during the study or for approximately 6 months after the last dose of blinded', 'investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the', 'study or for approximately 6 months after the last dose of blinded investigational', 'product.', '10.', 'Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent', 'within 1 week prior to randomization.', '11.', 'Subject has a history of active malignancies other than SCLC within the past', '2 years prior to study entry, with the exception of in situ cancer which was', 'curatively treated.', '37']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD-based) or', 'indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine', 'clinical trial, or known hypersensitivity or other contraindications to', 'rovalpituzumab tesirine or excipient contained in the drug formulation.', '13.', 'Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary', 'cells.', 'Rationale for Exclusion Criteria', '1, 10 - 13', 'To select the appropriate subject population', '2-7', 'For the safety of the subjects', '8 9', 'The impact of rovalpituzumab tesirine on pregnancy in humans is', 'unknown', '5.2.3', 'Prior and Concomitant Therapy', 'Any concomitant medication or vaccine (including over-the-counter or prescription', 'medicines, vitamins and/or herbal supplements) that the subject is receiving at the time of', 'study drug administration or receives during the study through the safety reporting period', '(Section 6.1.5), must be recorded along with the reason for use, date(s) of administration', 'including start and end dates, and dosage information including dose, route and frequency.', 'Any concomitant therapy given for a protocol-related AE should be recorded from the', 'time of informed consent.', 'The AbbVie TA MD should be contacted if there are any questions regarding concomitant', 'or prior therapies.', '5.2.3.1', 'Prior Therapy', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', '38']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'irinotecan; administration of Day 1 of the last cycle of first-line chemotherapy must be at', 'least 3 weeks but no more than 9 weeks prior to randomization. Subjects previously', 'treated for LD-SCLC are not eligible.', 'Subjects with central nervous system (CNS) metastases present prior to the initiation of', 'first-line chemotherapy will have completed definitive local treatment (e.g., surgery or', 'radiotherapy). Upon completion of first-line chemotherapy, subjects without a history of', 'CNS metastases must have been offered prophylacti cranial irradiation (PCI), if offering', 'this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. PCI regimen must', 'be consistent with those endorsed by the National Comprehensive Cancer Network', '(NCCN) or European Society for Medical Oncology (ESMO).', '5.2.3.2', 'Concomitant Therapy', 'All subjects enrolled will receive premedication consisting of dexamethasone/placebo.', 'Refer to Section 5.5.1, Treatments Administered for details.', 'There are no other required concomitant therapies. However, due to the potential for', 'rovalpituzumab tesirine-related skin photosensitivity, patients should be advised to avoid', 'direct and indirect sun exposure as much as possible from Cycle 1 Day 1 until 30 days', 'after the final dose. When sun exposure is unavoidable, patients should wear protective', 'clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm (SPF 30 or', 'greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the patient may', 'resume outdoor activities with appropriate sun protection including broad brimmed hat,', 'protective clothing and sunscreen SPF 30 or higher.', '5.2.3.2.1', 'Allowed Concomitant Therapy', 'Standard supportive care for drug-related toxicity is permitted, including growth factors', 'and blood product transfusions per local institutional standards. Other standard', 'supportive care for symptom control or drug-related toxicity is allowed, such as', 'analgesics, anti-emetics, electrolyte replacement, and hydration. Bone modifying agents', '39']\n\n###\n\n", "completion": "END"}